Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Oncologic and Triton BioSystems Merge to Form Aduro BioTech: Aduro to Focus on NT™ and TNT™ Systems for Solid Tumor Cancers

Abstract:
Two early stage cancer therapy companies, Oncologic and Triton BioSystems, have merged to create Aduro BioTech. Aduro, which is privately held, will be headquartered at the former Oncologic facility in Berkeley, California.

Oncologic and Triton BioSystems Merge to Form Aduro BioTech: Aduro to Focus on NT™ and TNT™ Systems for Solid Tumor Cancers

Berkeley, CA | Posted on June 2nd, 2008

Aduro will focus on the development of its proprietary and minimally invasive NT™ and TNT™ cancer therapies, which use patented iron oxide nano-particles to target and kill solid tumor cancers. The nano-particles are engineered to efficiently generate high levels of heat when exposed to an externally applied magnetic field, and this heat kills tumor cells without the toxicity or collateral damage that result from traditional chemotherapy or radiation treatments.

"There are several exciting aspects of the Aduro technology that we believe can offer significant improvements to current therapies," said Stephen T. Isaacs, CEO of Aduro. "We are developing a cancer therapy based on the low toxicity of iron oxide, which is an innocuous material currently used in a variety of medical applications. If successfully developed, the Aduro products will be an exceedingly important addition to the field of solid tumor cancer therapy."

According to the company, one of the major problems with current cancer therapy is the collateral damage to normal tissues, and that it's often not the failure of radiation or chemotherapeutic agent to kill the tumor that's the problem, but rather the inability to deliver a "knock-out" punch because of dose-limiting toxicity. The company believes that unlike radiation or chemotherapy, the Aduro NT™ and TNT™ particles will be innocuous until activation by an external (non-invasive) alternating magnetic field. Due to the low-toxicity of iron oxide and the targeting agents which guide the nano-particles to the tumor, Aduro believes its NT™ and TNT™ therapeutic products may be used at higher dose levels than current therapies, which in turn should provide significantly improved therapeutic outcomes.

Oncologic and Triton BioSystems Merge to Form Aduro BioTech

Mr. Isaacs said that the technology has been demonstrated to work in a murine (mouse) system with both direct and systemic infusions of the NT™ and TNT™ nano-particles. "We believe the NT™ (direct infusion) method is the shortest path to the clinic, and we hope to start a clinical trial for accessible head and neck cancer in 2009," Mr. Isaacs continued. "Our basic strategy is to be first to show direct clinical benefit with ‘thermal therapy' in humans, then to move on the more interesting systemic approach with the TNT™ method, which we believe holds promise for metastatic disease."

In 1991, Mr. Isaacs founded Cerus Corporation (NASD: CERS), where he served as CEO for fourteen years. During Isaacs' tenure, Cerus became a publicly traded company, entered several major corporate partnerships, raised over 250 million dollars, and brought its first product to market in Europe. He is joined by several seasoned cancer researchers, including Drs. Paul Chinn and Gary Braslawsky, who worked together at Biogen-Idec, where they led the development of Zevalin®, an FDA-approved radio-pharmaceutical used for the treatment of non-Hodgkin's lymphoma (a blood cancer).

Aduro BioTech simultaneously closed on its Series A financing round, which included a consortium of insiders and new investors. Terms of the financing were not disclosed.

© 2008 Aduro BioTech, Inc. TNT™ and NT™ are trademarks of Aduro; Zevalin®is a registered trademark of Cell Therapeutics, Inc.

####

For more information, please click here

Contacts:
Aduro BioTech
David S. Rose
510-848-4400 x101

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Discovery of nanotubes offers new clues about cell-to-cell communication July 2nd, 2015

Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Producing spin-entangled electrons July 2nd, 2015

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Portfolio Company, AgBiome, Announces Partnership to Accelerate the Discovery of Next Generation Insect-Resistant Crops July 1st, 2015

Chivalrous Knight Does Pro Bono June 27th, 2015

Exagan Raises €5.7 Million to Produce High-efficiency GaN-on-Silicon Power-switching Devices on 200mm Wafers: Leti-and-Soitec Spinout Focused on Becoming Leading European Source Of GaN Devices for Solar, Automotive, Telecoms and Infrastructure June 25th, 2015

Harris & Harris Group Portfolio Company D-Wave Systems Announces 1,000 Qubit Processor and is Discussed in the Economist June 23rd, 2015

Nanomedicine

Iranian Scientists Find Simple, Economic Method to Synthesize Antibacterial Nanoparticles July 2nd, 2015

Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015

Carnegie Mellon chemists characterize 3-D macroporous hydrogels: Methods will allow researchers to develop new 'smart' materials June 30th, 2015

Chitosan coated, chemotherapy packed nanoparticles may target cancer stem cells June 30th, 2015

Announcements

Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Producing spin-entangled electrons July 2nd, 2015

NIST Group Maps Distribution of Carbon Nanotubes in Composite Materials July 2nd, 2015

Acquisitions/Mergers/Splits

GLOBALFOUNDRIES Completes Acquisition of IBM Microelectronics Business: Transaction adds differentiating technologies, world-class technologists, and intellectual property July 1st, 2015

Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy June 3rd, 2015

Evident Thermoelectrics Acquires GMZ Energy: Investment Accelerates Launch Of Evident's Thermoelectric Modules For Waste Heat May 20th, 2015

Keysight Technologies Begins Trading as Independent Company November 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project